

SAGE WORKING GROUP ON YELLOW FEVER VACCINES

**Recommendations
for consideration by SAGE**

SAGE WORKING GROUP ON YELLOW FEVER VACCINES

10 year booster dose

- Based on currently available data, a single dose of yellow fever vaccine appears to confer life-long protective immunity against yellow fever disease. Therefore, a booster dose of yellow fever vaccine is not needed to maintain immunity.
- *However, further study is needed in certain groups, who may have suboptimal seroconversion rates following a single dose of the vaccine to determine if they may benefit from a single booster dose.*

SAGE WORKING GROUP ON YELLOW FEVER VACCINES

Use of YF vaccine in people ≥ 60 years old

- A risk assessment should take into account risk of acquiring yellow fever disease *versus* the risk of a potential adverse event following immunization.
- Vaccination should be recommended with caution and based on a risk-benefit assessment for any person ≥ 60 years of age who has not been vaccinated.

SAGE WORKING GROUP ON YELLOW FEVER VACCINES

- Note changes recommended in existing 2003 YF position paper

- Yellow fever vaccine is contraindicated for severely immunocompromised persons, including persons with AIDS or CD4+ counts < 200 cells/mm³.

- Yellow fever vaccination may be offered to asymptomatic HIV-infected persons with CD4+ counts ≥ 200 cells/mm³ who require vaccination.

- *Additional data on safety & immunogenicity should be obtained on the effect of vaccination in HIV-positive individuals.*

Use of YF vaccine in HIV- infected persons

SAGE WORKING GROUP ON YELLOW FEVER VACCINES

*Use of YF vaccine
in persons with
immunocompro-
mising conditions
(other than HIV)*

- **Note clarifications recommended in existing 2003 YF position paper, but further clarify immunocompromising conditions**

SAGE WORKING GROUP ON YELLOW FEVER VACCINES

Use of YF vaccine in persons with immunocompro- mising conditions (other than HIV)

Conditions and treatments that would be considered severely immunocompromising include: *i). certain 1° immunodeficiencies, ii). thymus disorder, iii). symptomatic HIV-infection or CD4+ T-lymphocyte values < 200 per mm³, iv). malignant neoplasm, v). recent hematopoietic stem cell transplantation, vi). use of drugs with known immunosuppressive or immunomodulatory properties , (e.g., high-dose systemic corticosteroids, alkylating drugs, antimetabolites, TNF- α inhibitors, IL-1 blocking agent, or other monoclonal antibodies targeting immune cells), and vii). current or recent radiation therapies targeting immune cells.*

SAGE WORKING GROUP ON YELLOW FEVER VACCINES

Co- administration of YF and other vaccines

- **Currently available data suggest that there is minimal impact on the reactogenicity and immunogenicity when YF vaccine is co-administered with other vaccines, with one notable exception; the co-administration of YF vaccine and MMR vaccine in young children, where immunogenicity appears to be compromised against several antigens.**
- *Additional studies are warranted on the co-administration of YF vaccine and other vaccines, in particularly MMR and meningococcal A vaccines.*

SAGE WORKING GROUP ON YELLOW FEVER VACCINES

Research questions

- *Transmission of YF vaccine virus by breastfeeding.*
- *Efficacy of YF and meningococcal vaccines when co-administered in EPI.*
- *Efficacy of YF and MMR vaccines when co-administered in EPI.*
- *Efficacy of YF and OPV vaccines when co-administered in EPI.*

SAGE WORKING GROUP ON YELLOW FEVER VACCINES

Impact of vaccination strategies on YF control

- **Control strategy for yellow fever should include sound epidemiologic surveillance and delivery of yellow fever vaccine through a complementary and optimized combination of EPI and mass preventive campaigns. Reactive campaigns should be conducted in response to yellow fever outbreaks if there is inadequate vaccination coverage within the population.**

SAGE WORKING GROUP ON YELLOW FEVER VACCINES

Research questions

- *Safety and immunogenicity of YF vaccine in persons with advanced AIDS*
- *Safety of YF vaccine in people ≥ 60 years.*
- *Safety of YF vaccine in people with immunocompromising conditions.*